LAMEA Oncology/Anti-Cancer Drugs Market -
Opportunities and Forecasts, 2014-2021, projects that the LAMEA oncology/cancer
drugs market would reach $17.0 billion by 2021, registering a CAGR of 8.6% from
2015 to 2021. Chemotherapy segment is expected to maintain a dominant share in
the LAMEA oncology/cancer drugs market during the forecast period.
High prevalence and rising incidence rates of major
types of cancers (such as breast cancer and prostate cancer), emerging
treatment algorithms and widespread use of anti-cancer drugs for treating
conditions such as blood cancer (leukemia) is expected to drive this market. In
addition, growing popularity of biological and targeted drug therapies, which
help in improving the patients’ survival time, are projected to provide
opportunities in the LAMEA oncology/anti-cancer drugs market. However, factors
such as high cost associated with cancer drugs and related side effects are
likely to affect the market growth.
Blood cancer segment is expected to maintain its
dominant position throughout the forecast period. This is attributed to the
higher incidence rates of blood cancer across the LAMEA region and growing
awareness about the early detection and treatment of blood cancer. However,
respiratory/lung cancer was the fastest growing segment registering a CAGR of
10.2% during the analysis period. Furthermore, commercialization of advanced
therapeutics such as biologic therapies (immunotherapies) and targeted
therapies are anticipated to increase the adoption of anti-cancer drugs in the
LAMEA region.
Key findings
of the study:
Immunotherapy (biologic therapy) is projected to be
the fastest growing segment, registering a CAGR of 12.2% during the forecast
period.
Chemotherapy is expected to dominate the LAMEA
oncology/cancer drugs market throughout the forecast period.
Blood cancer segment would lead the LAMEA
oncology/cancer drugs market through 2021.
Algeria is anticipated to be the fastest growing
country in the LAMEA oncology/anti-cancer drugs market, registering a CAGR of
12.8% between 2015 and 2021.
Brazil was the highest revenue generating country in
the LAMEA oncology/anti-cancer drugs market with about one third of market
share in 2015.
Saudi Arabia, is the leading country market from the
Middle East region and would continue to lead until 2020, owing to rising
incidence rates of cancer, high healthcare expenditure and gross national
income (GNI) in Saudi Arabia. Algeria, is expected to witness highest growth
rate because of considerable funding, urbanized healthcare facilities and
establishment of national healthcare systems. Furthermore, acquisition is the
key growth strategy adopted by the leading players in the market, which helped
companies to expand their oncology drugs business. In addition, the market
players have also adopted strategies, such as approval and collaborations, to
sustain the competition in the market. The key companies profiled in the report
include, Amgen Inc., AstraZeneca Plc., Roche Diagnostics, GlaxoSmithKline PLC,
Merck & Co., Novartis AG, AbbVie Inc. Sanofi, EIMC United Pharmaceuticals
(EUP) and Actavis plc.
For more information Visit at: http://mrr.cm/J3L
Find all Pharmaceutical
Manufacturing report at:
No comments:
Post a Comment
Note: only a member of this blog may post a comment.